



DRUG REVIEW

June 2023



UBRELVY® - A First-In-Class Therapy for the Treatment of Migraines

Migraines are a class of debilitating headaches that reduce patients' quality of life, work performance and productivity. It is the second leading cause of disability worldwide. Migraines affect approximately 8.3% of the Canadian population. They are characterized by a throbbing headache on one side of the head, associated with nausea, vomiting and aversion to light or sounds.

The goals of therapy for migraine management include rapid and consistent freedom of pain, a restored ability to function and increased quality of life. Management of migraines can be separated into prevention and treatment. Preventative strategies aim to reduce the occurrence of migraines and treatment aims to manage symptoms.

Current treatment strategies include the class of triptans. Despite being highly effective in reducing pain associated with migraines, triptans should be avoided in those with heart-related conditions. Ubrelvy offers an alternative treatment option for those who have a lack of response to triptans or are unable to use triptans.

Ubrelvy® has a unique mechanism of action, that is different to triptans. Clinical trials demonstrated that Ubrelvy is effective in reducing the pain that migraines cause. Trials further demonstrated that the patient may experience pain relief from migraines for up to 48 hours.

Ubrelvy is comparably priced to current migraine therapies, including the class of triptans. Ubrelvy offers patients experiencing migraines an alternative treatment course and will be fully covered under ClaimSecure plans.

Drug Name	Ubrelvy®
Drug Ingredients	Ubrogepant
Annual Cost	\$2,957
Coverage Details	Fully Covered

References:

1. Ubrelvy Product Monograph. Abbvie Corporation. November 2022.
2. Ubrogepant for the Treatment of Migraine. Dodick et al. 2019

ClaimSecure Inc. reserves the right to amend in part, or in its entirety, its coverage under ClaimSecure plans.

©2023 ClaimSecure Inc.

